TP53 mutation has also been positive in older patients (above 65 years old) more commonly in comparison with their younger counterparts, which adds to the statistics of poor prognosis and diminished relapse-free survival (RFS) rates in MDS-AML patients above 65 years of age [6]. This evidence concerns the gene TP53 and acute myeloid leukemia.